ClinicalTrials.gg
RecruitingNCT07604610EPIGRAPHUpdated May 22, 2026

Epicardial Fat Tissue and Cardiometabolic Risk in Russian and Asian Populations

An observational study in Epicardial Fat Tissue (EFT), Chronic Non-Communicable Diseases (NCDs) and Visceral Obesity, sponsored by National Medical Research Center for Therapy and Preventive Medicine. Recruiting at 1 site in Russia. Open to participants aged 50 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by National Medical Research Center for Therapy and Preventive Medicine · Observational

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
500
Ages
50 Years to 70 Years
Sex
All
01

Study summary

Visceral obesity is a well-established risk factor for the development of chronic non-communicable diseases (NCDs). Epicardial fat tissue (EFT) is located on the surface of the myocardium and may directly affect cardiac function and contribute to structural and functional remodeling.

According to the literature, increased EFT thickness is associated with a wide range of NCDs, disease severity, and prognosis.

The aim of this study is to investigate the associations between EFT thickness and clinical and anamnestic parameters, as well as to evaluate the prognostic value of this parameter in patients aged 50-70 years from the Russian Federation, Kazakhstan, Uzbekistan, and Kyrgyzstan.

Read the detailed description

The study is designed to:

  1. Assess physical examination findings, laboratory parameters, and comorbidities;
  2. Evaluate transthoracic echocardiography parameters;
  3. Analyze associations between EFT thickness and clinical and anamnestic characteristics;
  4. Determine threshold values of EFT thickness associated with structural and functional myocardial remodeling;
  5. Conduct follow-up via telephone to assess study endpoints;
  6. Evaluate the prognostic value of EFT thickness with respect to a composite endpoint.
02

Conditions studied

  • Epicardial Fat Tissue (EFT)
  • Chronic Non-Communicable Diseases (NCDs)
  • Visceral Obesity

Keywords

  • epicardial fat
  • echocardiography
  • cardiovascular risk
  • metabolic disorders
  • cohort study
03

In context

Noncommunicable Diseases

146 studies on the registry are indexed under Noncommunicable Diseases; 57 are open to participants now.

This study's planned enrollment of 500 is below the median of 1,674 across 48 observational studies indexed under Noncommunicable Diseases.

Browse Noncommunicable Diseases studies →

Lead sponsor

National Medical Research Center for Therapy and Preventive Medicine is the lead sponsor of 29 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients from the Russian Federation, Kazakhstan, Uzbekistan, and Kyrgyzstan

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 50-70 years undergoing transthoracic echocardiography in inpatient or outpatient settings;
  • Ability and willingness to provide .

Exclusion criteria

Exclusion Criteria:

  • Refusal to sign ;
  • Inability to perform transthoracic echocardiography or poor image quality;
  • Severe psychiatric disorders.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Observational cohort

    Patients aged 50-70 years undergoing transthoracic echocardiography (TTE) in inpatient or outpatient

06

What researchers measure

Primary outcomes

  1. Composite endpoint - all-cause mortality - hospitalizations - major adverse cardiovascular events (MACE)

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • National Medical Research Center for Therapy and Preventive Medicine
    Moscow, Russia
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2026 (actual). Primary completion is estimated for Mar 2027, 10 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2026
First posted
May 22, 2026
StartActual
May 4, 2026
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2028
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07604610
Lead sponsor
National Medical Research Center for Therapy and Preventive Medicine
Responsible party
Sponsor
First posted
May 22, 2026
Start date
May 4, 2026
Primary completion
Mar 2027 (estimated)
Completion
Mar 2028 (estimated)
Last update
May 22, 2026

Study contacts

Olga Dzhioeva, MD, Associate Professor
Contact
odzhioeva@gnicpm.ru
+79166141821
Elizaveta Rogozhkina, PhD
Contact
lizarogozkina@gmail.com
+79371047331

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion